PST2744 (hydrochloride) manufacturers
- Istaroxime hydrochloride
-
- $15.00 / 1KG
-
2021-07-13
- CAS:374559-48-5
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Istaroxime hydrochloride
-
- $15.00 / 1KG
-
2021-07-10
- CAS:374559-48-5
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | PST2744 (hydrochloride) Basic information |
| Product Name: | PST2744 (hydrochloride) | | Synonyms: | IstaroxiMe (hydrochloride);PST 2744 (hydrochloride);PST2744 (hydrochloride);PST-2744 (hydrochloride);(5alpha)-Androstane-3,6,17-trione 3-[O-(2-aminoethyl)oxime] monohydrochloride;Istaroxime hydrochloride, >=98%;Istaroxime hydrochloride(PST2744);PST2774;PST-2774 | | CAS: | 374559-48-5 | | MF: | C21H33ClN2O3 | | MW: | 396.96 | | EINECS: | | | Product Categories: | | | Mol File: | 374559-48-5.mol |  |
| | PST2744 (hydrochloride) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | color | White to light brown |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | STOT RE 2 |
| | PST2744 (hydrochloride) Usage And Synthesis |
| Uses | Istaroxime hydrochloride is a Na+/K+-ATPase inhibitor (IC50=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA 2) activator. | | Biological Activity | istaroxime hydrochloride(pst2744) is a novel inhibitor of na+/k+-atpase with ic50 value of 0.43±0.15μm [1].istaroxime is a steroidal drug unrelated to cardiac glycosides that improves cellular calcium cycling. the inhibition of na+/k+-atpase induces cytosolic calcium accumulation during systole (inotropism). clinical studies has been done with istaroxime in phase ii. istaroxime could be a promising alternative for patients with acute heart failure syndrome for whom the therapeutic options are currently limited [2]. | | in vitro | studies show that istaroxime can inhibit the activity of na+/k+-atpase from dog kidney without significant interaction with other several receptors. it demonstrates the selectivity of istaroxime. ex vivo studies show the inotropic effect can be achieved up to 60% for istaroxime. istaroxime can also increase the force of contraction of guinea pig paced left atria in the range 0.3 to 30μm. in vivo assays prove istaroxime is consistently safer than digoxin [1]. | | in vivo | Istaroxime (PST2744) induces a progressive increase in +dP/dtmax throughout the infusion that reaches 80% (ED80) at the cumulative dose of 1.89±0.37 mg/kg and a peak of 140±3.5% at the dose (EDmax) of 4.88±0.6 mg/kg[3]. | | target | Na+/K+ ATPase | | references | [1] r. micheletti, g. g. mattera, m. rocchetti, a. schiavone, m. f. loi, a. zaza, r. j. p. gagnol, s. de munari, p. melloni, p. carminati, g. bianchi, and p. ferrari. pharmacological profile of the novel inotropic agent (e,z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (pst2744). the journal of pharmacology and experimental therapeutics. 2002, 303 (2): 592-600.
[2] suruchi aditya, aditya rattan. istaroxime: a rising star in acute heart failure. journal of pharmacology and pharmacotherapeutics. 2012, 3(4): 353-355. |
| | PST2744 (hydrochloride) Preparation Products And Raw materials |
|